Cognition Therapeutics (CGTX)
(Delayed Data from NSDQ)
$0.71 USD
0.00 (0.20%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.67 -0.04 (-5.82%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Cognition Therapeutics, Inc. (CGTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.20 | $11.00 | $1.00 | 773.24% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Cognition Therapeutics, Inc. comes to $6.20. The forecasts range from a low of $1.00 to a high of $11.00. The average price target represents an increase of 773.24% from the last closing price of $0.71.
Analyst Price Targets (5 )
Broker Rating
Cognition Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, four are Strong Buy, representing 66.67% of all recommendations. A month ago, Strong Buy represented 83.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CGTX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 5 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 1 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.67 | 1.67 | 1.33 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/6/2024 | B. Riley Securities | Mayank Mamtani | Strong Buy | Hold |
7/31/2024 | LadenburgThalmann | Aydin Huseynov | Strong Buy | Strong Buy |
7/30/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Hold |
7/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/6/2024 | Chardan Capital Markets | Daniil Gataulin | Not Available | Strong Buy |
5/29/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.67 |
ABR (Last week) | 1.67 |
# of Recs in ABR | 6 |
Average Target Price | $6.20 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.19 |